發(fā)布時間：2018-02-13 18:28

  本文關鍵詞： 急性心肌梗死 心力衰竭 阿托伐他汀 重組人腦利鈉肽 療效 安全性　出處：《中國藥房》2016年09期 　論文類型：期刊論文

【摘要】：目的:觀察阿托伐他汀聯(lián)合重組人腦利鈉肽(rhBNP)治療急性心肌梗死(AMI)合并心力衰竭的療效和安全性。方法:160例AMI合并心力衰竭患者隨機分均為A組和B組。A組患者給予肝素、阿司匹林、氯吡格雷等藥物,同時限制鈉水攝入,給予利尿藥、β受體阻滯藥,合并呼吸困難者給予面罩吸氧,合并肺感染患者給予抗菌藥物等常規(guī)治療;B組患者在A組治療的基礎上給予凍干rhBNP負荷劑量1.5μg/kg,3 min內靜脈推注完,后以0.007 5μg/(kg·min)維持靜脈滴注24 h,連用7 d+每晚睡前服用阿托伐他汀鈣片40 mg,每日1次,連用14 d。兩組療程均為14 d。觀察兩組患者的臨床療效,治療前后血清前膠原氨基末端肽(PⅢNP)、超敏C反應蛋白(hs-CRP)、去甲腎上腺素(NE)、血肌酐(Cr)、左心室射血分數(shù)(LVEF)、左心室舒張末期容積(LVEDV)、左心室收縮末期容積(LVESV)及不良反應發(fā)生情況。結果:B組患者總有效率顯著高于A組,差異有統(tǒng)計學意義(P0.05)。治療前,兩組患者PⅢNP、hs-CRP、NE、Cr、LVEF、LVEDV、LVESV比較,差異均無統(tǒng)計學意義(P0.05)。治療后,兩組患者PⅢNP、hs-CRP、NE、Cr、LVEDV、LVESV均顯著低于同組治療前,且B組低于A組;LVEF顯著高于同組治療前,且B組高于A組,差異均有統(tǒng)計學意義(P0.05)。兩組患者不良反應發(fā)生率比較,差異無統(tǒng)計學意義(P0.05)。結論:在常規(guī)治療的基礎上,阿托伐他汀聯(lián)合rhBNP治療AMI合并心力衰竭療效顯著,可有效提高心輸出量,改善心室重塑,且安全性相當。
[Abstract]:Objective: to observe the efficacy and safety of Atto vastatin combined with recombinant human brain natriuretic peptide (rhBNP) in the treatment of acute myocardial infarction (AMI) with heart failure. Aspirin, clopidogrel and other drugs, at the same time limit the intake of sodium, give diuretics, 尾 -receptor blockers, combined with breathing difficulties given mask oxygen, Patients with pulmonary infection were treated with antibiotics and other routine therapy. Group B received intravenous injection of freeze-dried rhBNP loading dose of 1.5 渭 g / kg / kg for 3 min on the basis of group A treatment. After 24 hours of intravenous drip with 0.007.5 渭 g / kg / min, 40 mg of Atto vastatin calcium tablet was taken before bedtime every night for 7 days, once a day for 14 days. The clinical efficacy of the two groups was observed for 14 days. Serum procollagen amino-terminal peptide P 鈪，

本文編號：1508813